---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-078937"
form_type: "8-K"
ticker: "RAPH"
cik: "0001415397"
company_name: "Raphael Pharmaceutical Inc."
filed_at: "2026-07-17T13:20:50+00:00"
generated_at: "2026-07-17T13:22:04.930380+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Chairman and CFO resign; Uri Tadelis appointed as new CFO

## Summary
- Ajay Kumar Dhadha resigned as Chairman and Director effective June 30, 2026.
- Guy Ofir resigned as CFO, General Counsel, and Director effective July 16, 2026.
- Both resignations were not due to any disagreement with the company.
- Uri Tadelis appointed as CFO effective July 16, 2026.

## SEC filing metadata
- accession: 0001213900-26-078937
- form_type: 8-K
- ticker: RAPH
- cik: 0001415397
- company_name: Raphael Pharmaceutical Inc.
- filed_at: 2026-07-17T13:20:50+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/ea0298326-8k_raphael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-078937
- JSON: https://secwatch.observer/filing/0001213900-26-078937.json
- Plain text: https://secwatch.observer/filing/0001213900-26-078937.txt

## Key facts
- Executive change
  Ajay Kumar Dhadha resigned as Chairman of the Board of Directors at Raphael Pharmaceutical Inc..
  - Action: resigned
  - Role: Chairman of the Board of Directors
  source text: Mr. Ajay Kumar Dhadha voluntarily resigned from his positions as Chairman of the Board of Directors and Director of the Company, effective June 30, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm
- Executive change
  Guy Ofir resigned as Chief Financial Officer, General Counsel, and Director at Raphael Pharmaceutical Inc..
  - Action: resigned
  - Role: Chief Financial Officer, General Counsel, and Director
  source text: Mr. Guy Ofir voluntarily resigned from his positions as Chief Financial Officer, General Counsel, and Director of the Company, effective July 16, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm
- Executive change
  Uri Tadelis was appointed as Chief Financial Officer at Raphael Pharmaceutical Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective July 16, 2026, the Company appointed Mr. Uri Tadelis as its Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1415397/000121390026078937/0001213900-26-078937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.